MYCN
Reaktivität: Human
WB
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Optimal dilution of the n-Myc antibody should be determined by the researcher.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.2 mg/mL
Buffer
0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store the n-Myc antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Target
MYCN
(N-Myc Proto-Oncogene Protein (MYCN))
Andere Bezeichnung
n-Myc
Hintergrund
The v-Myc oncogene, initially identified in the MC29 avian retrovirus, causes myelocytomas, carcinomas, sarcomas and lymphomas, and belongs to a family of oncogenes conserved throughout evolution. In humans, the family consists of five genes: c-Myc, N-Myc, R-Myc, L-Myc and B-Myc. Amplification of the N-Myc gene has been found in human neuroblastomas and cell lines. Its amplification correlates well with the stage of neuroblastoma disease. Immunological studies have shown that the human N-Myc gene encodes a nuclear phosphoprotein that exhibits relatively short (30 min) half life in vivo. The prototype member of the family, c-Myc p67, binds DNA in a sequence-specific manner subsequent to dimerization with a second basic region helix-loop-helix leucine zipper motif protein, designated Max.